More Insulin Innovation To Come, Says Novo CEO Sorensen
This article was originally published in The Pink Sheet Daily
Executive Summary
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices
You may also be interested in...
Degludec Advisory Committee Is Another De Facto Delay For Novo
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
New Long-Acting Insulin Offerings Could Derail Lantus Franchise
Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.
Novo Nordisk Brings Renewed Education Efforts, But Not New Products, To Japan In 2012
Novo Nordisk pushes the benefits of early diabetes treatment to spur Victoza and insulin growth.